Abstract
(87.2%, 74.4%) compared to the HAS1-HYAL1 (78.7%, 73.2%), HAS3HYAL1 (80.5%, 68.3%), HAS1-HAS2 (83%, 64.6%) and HAS2-HAS3 (85.1%, 67%) combinations. The HAS2-HYAL1 combination exhibited high sensitivity in detecting low(85.7%) and high-(87.8%) grade tumors. Five patients with a history of bladder cancer recurred within 6 months and 4 of them were positive for the HAS2HYAL1 and HAS2-HYAL1 combinations. CONCLUSIONS: A real time RT-PCR based assay for HYAL1 and HAS mRNA measurement detects bladder cancer with high
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
